| 초록 |
Cancer immunotherapy has been drawing growing attention as a novel promising therapeutic modality for cancer. Among several immunotherapeutic approaches, second generation CD19-targeting chimeric antigen receptor (CAR) T cells engineered with costimulatory signaling domains have generated unprecedented anti-leukemic responses in patients with refractory B-cell leukemia. In light of their clinical promise, there has been an explosion of interest in CAR-T cells for cancer immunotherapy, especially for the treatment of relapsed, refractory malignancies. However, the inability to control the activity of this potent “live” drug has resulted in severe treatment related toxicities and the constraint in targeting more than one antigen have limited its general application. In this talk, I will discuss our recent research efforts focusing on addressing these limitations of current CAR-T therapy. |
